Inventor · disambiguated record
Cecile Bauche
Also filed as: BAUCHE CECILE · BAUCHE CÉCILE
13 granted patents·15 pending applications·27 citations·filing 2003–2021
87Inventor score
Top patents by PatentIndex Score
28 records- 0184US10752668B2Lentiviral vectors for regulated expression of a chimeric antigen receptor moleculeTHERAVECTYS·Filed 2015·Granted Aug 25, 2020·8 cites·5 claims
- 0282US9657311B2Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequenceTHERAVECTYS·Filed 2014·Granted May 23, 2017·5 cites·21 claims
- 0381US7906123B1Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereofPASTEUR INSTITUT·Filed 2007·Granted Mar 15, 2011·8 cites·17 claims
- 0471US9410139B2Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigensDADAGLIO GILLES·Filed 2008·Granted Aug 9, 2016·3 cites·5 claims
- 0569US9370564B2Vectors for molecule delivery to CD11b expressing cellsLECLERC CLAUDE·Filed 2011·Granted Jun 21, 2016·2 cites·22 claims
- 0665US8951535B2Lentiviral vectors containing an MHC class I promoterTHERAVECTYS·Filed 2013·Granted Feb 10, 2015·1 cites·19 claims
- 0754US10004794B2Vectors for molecule delivery to CD11b expressing cellsPASTEUR INSTITUT·Filed 2016·Granted Jun 26, 2018·0 cites·16 claims
- 0851US2005238637A1Vectors for molecule delivery to CD11b expressing cellsCENTRE NAT RECH SCIENT·Filed 2005·Application pending·0 cites
- 0950US2005271679A1Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigensDADAGLIO GILLES·Filed 2004·Application pending·0 cites
- 1050US2021009653A1Lentiviral vectors for regulated expression of a chimeric antigen receptor moleculeTHERAVECTYS·Filed 2020·Application pending·0 cites
- 1148US9752160B2Use of non-subtype B gag proteins for lentiviral packagingTHERAVECTYS·Filed 2012·Granted Sep 5, 2017·0 cites·13 claims
- 1248US2023140346A1Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ CellsIXAKA FRANCE·Filed 2021·Application pending·0 cites
- 1347US2017362607A1Use of non-subtype b gag proteins for lentiviral packagingTHERAVECTYS·Filed 2017·Application pending·0 cites
- 1446US2010310594A1Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigensINST PASTEUR A CORP OF FRANCE·Filed 2010·Application pending·0 cites
- 1546US2022403391A1Aptamer-Based Multispecific Therapeutic AgentsIXAKA FRANCE·Filed 2020·Application pending·0 cites
- 1646US2004001867A1Vectors for molecule delivery to CD11b expressing cellsFiled 2003·Application pending·0 cites
- 1746US2015182617A1Glycoproteins for pseudotyping lentivectorsTHERAVECTYS·Filed 2013·Application pending·0 cites
- 1845US2022403416A1Polymer-Encapsulated Viral Vectors for In Vivo Genetic TherapyIXAKA FRANCE·Filed 2020·Application pending·0 cites
- 1944US2022251562A1Anti-CD3 Aptamers for Use in Cell Targeting and LabelingIXAKA FRANCE·Filed 2020·Application pending·0 cites
- 2044US2007026022A1Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigensDADAGLIO GILLES·Filed 2006·Application pending·0 cites
- 2144US2006159697A1Modified bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereofLECLERC CLAUDE·Filed 2005·Application pending·0 cites
- 2243US12209243B2Aptamer-based CAR T-cell switchALAYA BIO INC·Filed 2019·Granted Jan 28, 2025·0 cites·26 claims
- 2342US11638752B2Viral vector constructs for expression of genetic adjuvants activating the STING pathwayARATINGA BIO AIO·Filed 2017·Granted May 2, 2023·0 cites·13 claims
- 2440US2020360297A1Polymer-Encapsulated Viral Vectors for Genetic TherapyARATINGA BIO TNP·Filed 2019·Application pending·0 cites
- 2538US2022389158A1DMSO-Free Synthesis of Oligopeptide-Modified Poly(Beta-Amino Ester)s and Their Use in Nanoparticle Delivery SystemsIXAKA FRANCE·Filed 2020·Application pending·0 cites
- 2636US11674153B2Viral vector constructs for expression of genetic adjuvants activating the CD40 and STING pathwaysARATINGA BIO AIO·Filed 2017·Granted Jun 13, 2023·0 cites·10 claims
- 2736US10538785B2Lyophilized lentiviral vector particles, compositions and methodsBAUCHE CECILE·Filed 2014·Granted Jan 21, 2020·0 cites·25 claims
- 2830US9987351B2Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1THERAVECTYS·Filed 2015·Granted Jun 5, 2018·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →